Novoheart Grants Stock Options

VANCOUVER, British Columbia, Oct. 08, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announces that it has granted incentive stock options to purchase an aggregate of 1,150,000 common shares of the Company (the “Options”) to non-executive directors of the Company. Option Grants The Options have […]

Quantum Genomics Enters Into Exclusive Negotiations for its First Partnership

The Company has entered into exclusive negotiations with a leading cardiology laboratory in South America to sign its first regional partnership PARIS and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC, OTCQX – QNNTF), a biopharmaceutical company specializing in developing a new drug class that directly targets […]

Integer Announces Acquisition of US BioDesign Assets

PLANO, Texas, Oct. 07, 2019 (GLOBE NEWSWIRE) — Integer Holdings Corporation (“Integer”) (NYSE:ITGR), a leading medical device outsource manufacturer, today announced it has purchased certain assets of US BioDesign, a manufacturer of complex braided biomedical structures for disposable and implantable medical devices headquartered in Quakertown, Pa. The acquisition will add […]

AngioDynamics Acquires Eximo Medical, Ltd. and its Innovative 355nm Laser Atherectomy Technology

LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has acquired Eximo Medical, Ltd., an early commercial stage, medical device company, and its proprietary 355nm wavelength laser-technology platform for $46 million in […]

Quantum Genomics Reports First Half 2019 Financial Results and Provides Corporate Update

Arterial hypertension: preparing for the pivotal Phase III study of firibastat in patients with resistant arterial hypertension Heart failure: the first patients were enrolled in June in QUORUM, a Phase IIb study of firibastat in heart failure PARIS and NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC, OTCQX […]

Verve Therapeutics Appoints Cardiologist Andrew Bellinger, M.D., Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary artery disease, today announced the appointment of physician and scientist Andrew Bellinger, M.D., Ph.D., as the company’s chief scientific officer. Dr. Bellinger joins Verve from […]

Endotronix Closes Expanded Series D Financing Round of $70 Million for Heart Failure Solution

LISLE, Ill, Oct. 1, 2019 /PRNewswire/ — Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure (HF), today announced the expansion of its Series D financing round, bringing the total for the round to $70 million. The expansion syndicate for the LSP-led round includes new investment from an additional […]